BridgeBio Pharma, Inc. (BIT:1BBIO)
Italy flag Italy · Delayed Price · Currency is EUR
33.96
+0.01 (0.03%)
At close: May 2, 2025

BridgeBio Pharma Company Description

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.

The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.
Country United States
Founded 2015
Industry Biological Products, Except Diagnostic Substances
Employees 730
CEO Neil Kumar

Contact Details

Address:
3160 Porter Drive
Palo Alto, Delaware 94304
United States
Phone 650 391 9740
Website bridgebio.com

Stock Details

Ticker Symbol 1BBIO
Exchange Borsa Italiana
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Neil Kumar Chief Executive Officer
Thomas Trimarchi Chief Financial Officer